 HONG KONG and SHANGHAI, China and FLORHAM PARK, N,J., Sept. 13, 2021 GLOBE NEWSWIRE -- HUTCHMED China Limited HUTCHMED NasdaqAIM: HCM; HKEX: 13 today announces that the Center for Drug Evaluation of Chinas National Medical Products Administration NMPA has granted Breakthrough Therapy Designation BTD to amdizalisib HMPL-689, a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma FL, a subtype of non-Hodgkins lymphoma NHL. 